JP2015511241A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015511241A5 JP2015511241A5 JP2014558094A JP2014558094A JP2015511241A5 JP 2015511241 A5 JP2015511241 A5 JP 2015511241A5 JP 2014558094 A JP2014558094 A JP 2014558094A JP 2014558094 A JP2014558094 A JP 2014558094A JP 2015511241 A5 JP2015511241 A5 JP 2015511241A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- granules
- organic acid
- composition according
- acceptable excipient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 37
- 239000008187 granular material Substances 0.000 claims 16
- 150000007524 organic acids Chemical class 0.000 claims 16
- 239000000546 pharmaceutical excipient Substances 0.000 claims 14
- 239000002245 particle Substances 0.000 claims 13
- KSGXQBZTULBEEQ-UHFFFAOYSA-N dabigatran etexilate Chemical compound C1=CC(C(N)=NC(=O)OCCCCCC)=CC=C1NCC1=NC2=CC(C(=O)N(CCC(=O)OCC)C=3N=CC=CC=3)=CC=C2N1C KSGXQBZTULBEEQ-UHFFFAOYSA-N 0.000 claims 10
- 229960000288 dabigatran etexilate Drugs 0.000 claims 9
- 238000002156 mixing Methods 0.000 claims 9
- 239000010410 layer Substances 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 239000011253 protective coating Substances 0.000 claims 6
- 239000011230 binding agent Substances 0.000 claims 5
- 238000009472 formulation Methods 0.000 claims 5
- 239000002552 dosage form Substances 0.000 claims 4
- 239000012458 free base Substances 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- 206010003658 Atrial Fibrillation Diseases 0.000 claims 3
- 208000005189 Embolism Diseases 0.000 claims 3
- 208000006011 Stroke Diseases 0.000 claims 3
- 239000011248 coating agent Substances 0.000 claims 3
- 238000000576 coating method Methods 0.000 claims 3
- 239000007902 hard capsule Substances 0.000 claims 3
- 238000013150 knee replacement Methods 0.000 claims 3
- 239000000314 lubricant Substances 0.000 claims 3
- 230000001050 lubricating effect Effects 0.000 claims 3
- 239000008188 pellet Substances 0.000 claims 3
- 238000001356 surgical procedure Methods 0.000 claims 3
- 230000009885 systemic effect Effects 0.000 claims 3
- 238000011541 total hip replacement Methods 0.000 claims 3
- 239000007931 coated granule Substances 0.000 claims 2
- 235000005985 organic acids Nutrition 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- 206010014522 Embolism venous Diseases 0.000 claims 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims 1
- 229960003850 dabigatran Drugs 0.000 claims 1
- YBSJFWOBGCMAKL-UHFFFAOYSA-N dabigatran Chemical compound N=1C2=CC(C(=O)N(CCC(O)=O)C=3N=CC=CC=3)=CC=C2N(C)C=1CNC1=CC=C(C(N)=N)C=C1 YBSJFWOBGCMAKL-UHFFFAOYSA-N 0.000 claims 1
- 229960004951 dabigatran etexilate mesylate Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000005469 granulation Methods 0.000 claims 1
- 230000003179 granulation Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 208000004043 venous thromboembolism Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN461/MUM/2012 | 2012-02-21 | ||
| IN461MU2012 | 2012-02-21 | ||
| PCT/EP2013/053426 WO2013124340A1 (en) | 2012-02-21 | 2013-02-21 | Oral pharmaceutical compositions of dabigatran etexilate |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015511241A JP2015511241A (ja) | 2015-04-16 |
| JP2015511241A5 true JP2015511241A5 (enExample) | 2016-03-31 |
| JP6215239B2 JP6215239B2 (ja) | 2017-10-18 |
Family
ID=47739283
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014558094A Active JP6215239B2 (ja) | 2012-02-21 | 2013-02-21 | ダビガトランエテキシラートの経口医薬組成物 |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US11013729B2 (enExample) |
| EP (2) | EP3858337A3 (enExample) |
| JP (1) | JP6215239B2 (enExample) |
| KR (1) | KR102090242B1 (enExample) |
| CN (2) | CN104114158A (enExample) |
| AU (1) | AU2013224146B2 (enExample) |
| BR (1) | BR112014020474B1 (enExample) |
| CA (1) | CA2864423C (enExample) |
| CY (1) | CY1124678T1 (enExample) |
| DK (1) | DK2817000T3 (enExample) |
| ES (1) | ES2895918T3 (enExample) |
| HR (1) | HRP20211606T1 (enExample) |
| HU (1) | HUE056194T2 (enExample) |
| IL (1) | IL234032B (enExample) |
| IN (1) | IN2014DN06734A (enExample) |
| JO (1) | JO3616B1 (enExample) |
| LT (1) | LT2817000T (enExample) |
| MX (1) | MX368868B (enExample) |
| NZ (1) | NZ628301A (enExample) |
| PL (1) | PL2817000T3 (enExample) |
| PT (1) | PT2817000T (enExample) |
| RS (1) | RS62566B1 (enExample) |
| RU (1) | RU2633482C2 (enExample) |
| SI (1) | SI2817000T1 (enExample) |
| SM (1) | SMT202100608T1 (enExample) |
| WO (1) | WO2013124340A1 (enExample) |
| ZA (1) | ZA201405855B (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE056194T2 (hu) | 2012-02-21 | 2022-01-28 | Towa Pharmaceutical Europe S L | Dabigatrán-etexilát orális gyógyszerészeti készítményei |
| CN111012756B (zh) * | 2013-06-21 | 2023-06-13 | 四川海思科制药有限公司 | 一种达比加群酯药物组合物及其制备方法 |
| CN104414995A (zh) * | 2013-09-04 | 2015-03-18 | 天津汉瑞药业有限公司 | 甲磺酸达比加群酯的药用组合物 |
| EP2853260A1 (en) * | 2013-09-27 | 2015-04-01 | ratiopharm GmbH | Pharmaceutical preparation comprising dabigatran etexilate bismesylate |
| WO2015071841A1 (en) | 2013-11-12 | 2015-05-21 | Druggability Technologies Holdings Limited | Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
| CN104784147B (zh) * | 2014-01-20 | 2018-01-23 | 成都苑东生物制药股份有限公司 | 一种甲磺酸达比加群酯胶囊药物组合物及其制备方法 |
| WO2015113324A1 (zh) * | 2014-01-30 | 2015-08-06 | 杭州领业医药科技有限公司 | 达比加群酯及其盐的投药制剂及其制备方法 |
| CN104922092A (zh) * | 2014-03-19 | 2015-09-23 | 陕西天森药物研究开发有限公司 | 一种通过包裹法制备的达比加群酯或其盐和水合物的药物组合 |
| IN2014MU01042A (enExample) | 2014-03-26 | 2015-10-02 | Cadila Healthcare Ltd | |
| CN104095830A (zh) * | 2014-05-22 | 2014-10-15 | 万特制药(海南)有限公司 | 一种甲磺酸盐达比加群酯胶囊的制备方法 |
| CN104825422B (zh) * | 2014-09-29 | 2017-12-12 | 普济生物科技（台州）有限公司 | 含达比加群酯甲磺酸盐的药物组合物及其制备方法 |
| CN105560206A (zh) * | 2014-10-13 | 2016-05-11 | 重庆圣华曦药业股份有限公司 | 一种达比加群酯胶囊的制备 |
| US10675276B2 (en) * | 2014-11-03 | 2020-06-09 | Hangzhou Solipharma Co., Ltd. | Dosing preparation of dabigatran etexilate or a salt thereof and a preparation method thereof |
| EP3251672B1 (en) | 2014-12-31 | 2023-02-01 | Shenzhen Pharmacin Co., Ltd. | Pharmaceutical composition comprising dabigatran etexilate and preparation method therefor |
| WO2017103945A1 (en) * | 2015-12-15 | 2017-06-22 | Strides Shasun Limited | Pharmaceutical compositions |
| CN106890148A (zh) * | 2015-12-21 | 2017-06-27 | 青岛黄海制药有限责任公司 | 一种达比加群酯片剂及其制备 |
| WO2017111637A1 (en) | 2015-12-23 | 2017-06-29 | Zaklady Farmaceutyczne Polpharma Sa | Pharmaceutical composition comprising dabigatran or a pharmaceutically acceptable salt thereof |
| JP2018184375A (ja) * | 2017-04-27 | 2018-11-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ダビガトランエテキシラート又は医薬的に許容されるその塩を含む錠剤及びその製造方法 |
| TR201706848A2 (tr) * | 2017-05-10 | 2018-11-21 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Dabigatran eteksi̇lat i̇çeren kati oral farmasöti̇k kompozi̇syonlar |
| WO2019004980A2 (en) * | 2017-05-10 | 2019-01-03 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | SOLID ORAL PHARMACEUTICAL COMPOSITIONS OF DABIGATRAN DEXILATE |
| TR201722353A2 (tr) * | 2017-12-27 | 2019-07-22 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Dabi̇gatran eteksi̇lat i̇çeren oral uygulama i̇çi̇n farmasöti̇k formülasyon |
| TR201722323A2 (tr) | 2017-12-27 | 2019-07-22 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Dabi̇gatranin oral farmasöti̇k kompozi̇syonlari |
| TR201722630A2 (enExample) | 2017-12-28 | 2019-07-22 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | |
| CN110339193B (zh) | 2018-04-04 | 2022-04-29 | 上海汉都医药科技有限公司 | 含达比加群酯的药物组合物及其制备方法 |
| WO2020032885A2 (en) | 2018-05-04 | 2020-02-13 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Capsule-in-capsule compositions of dabigatran etexilate |
| TR201905308A2 (tr) * | 2019-04-09 | 2020-10-21 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | A capsule formulation of dabigatran etexilate |
| CN113577067B (zh) * | 2021-06-03 | 2023-08-15 | 北京福元医药股份有限公司 | 一种甲磺酸达比加群酯药物制剂 |
| CN115006363A (zh) * | 2022-06-23 | 2022-09-06 | 上海信谊万象药业股份有限公司 | 一种牡蛎碳酸钙咀嚼片及其制备方法 |
| WO2024175037A1 (zh) * | 2023-02-21 | 2024-08-29 | 广州玻思韬控释药业有限公司 | 达比加群酯或其药物可接受的盐的微丸 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6087380A (en) | 1949-11-24 | 2000-07-11 | Boehringer Ingelheim Pharma Kg | Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions |
| JPH04103525A (ja) | 1990-08-22 | 1992-04-06 | Sanwa Kagaku Kenkyusho Co Ltd | 難水溶性薬物の持続性製剤化方法 |
| PE121699A1 (es) | 1997-02-18 | 1999-12-08 | Boehringer Ingelheim Pharma | Heterociclos biciclicos disustituidos como inhibidores de la trombina |
| KR20010012402A (ko) * | 1997-05-09 | 2001-02-15 | 세이지 파마슈티칼스, 인크. | 안정한 약제학적 경구 투여형 |
| US6174548B1 (en) | 1998-08-28 | 2001-01-16 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
| CN1264574C (zh) * | 2000-09-06 | 2006-07-19 | 田边制药株式会社 | 口服制剂 |
| NZ527585A (en) | 2001-02-15 | 2005-04-29 | Tanabe Seiyaku Co | Tablets quickly disintegrated in oral cavity |
| CA2476054C (en) * | 2002-03-07 | 2011-11-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical composition for the oral administration of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino)-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino)-propionic acid ethyl ester and the salts thereof |
| US20030181488A1 (en) * | 2002-03-07 | 2003-09-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof |
| DE10209985A1 (de) * | 2002-03-07 | 2003-09-25 | Boehringer Ingelheim Pharma | Oral zu applizierende Darreichungsform für 3-[(2-{[4-(Hexyloxycarbonylaminoimino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propinsäure-ethylester und dessen Salze |
| DE10337697A1 (de) | 2003-08-16 | 2005-03-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Tablette enthaltend 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenyl-amino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester oder dessen Salze |
| DE10339862A1 (de) | 2003-08-29 | 2005-03-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel |
| US8709476B2 (en) * | 2003-11-04 | 2014-04-29 | Supernus Pharmaceuticals, Inc. | Compositions of quaternary ammonium compounds containing bioavailability enhancers |
| MXPA06014066A (es) | 2004-06-02 | 2007-02-15 | Pharmacyclics Inc | Inhibicion de factor viia. |
| ES2438017T3 (es) | 2004-07-30 | 2014-01-15 | Methylgene Inc. | Inhibidores de la señalización del receptor del VEGF y del receptor del HGF |
| EP1820506B1 (en) | 2006-02-09 | 2008-03-26 | Teva Pharmaceutical Industries Ltd. | Dipyridamole extended-release formulations and process for preparing same |
| US20080069891A1 (en) * | 2006-09-15 | 2008-03-20 | Cima Labs, Inc. | Abuse resistant drug formulation |
| EP2271317B1 (de) | 2008-03-28 | 2017-04-19 | Boehringer Ingelheim International GmbH | Verfahren zur herstellung von säurepellets |
| US20110129538A1 (en) | 2008-03-28 | 2011-06-02 | Boehringer Ingelheim International Gmbh | Process for preparing orally administered dabigatran formulations |
| JP2011527318A (ja) * | 2008-07-14 | 2011-10-27 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ダビガトランを含有する医薬組成物の製造方法 |
| SI2542224T1 (sl) * | 2010-03-01 | 2014-10-30 | Ratiopharm Gmbh | Oralni farmacevtski sestavek, ki vsebuje dabigatran eteksilat |
| PL2588090T3 (pl) * | 2010-07-01 | 2017-12-29 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Doustne farmaceutyczne postacie dawkowania zawierające eteksylan dabigatranu i jego farmaceutycznie dopuszczalne sole |
| WO2012162492A1 (en) | 2011-05-24 | 2012-11-29 | Teva Pharmaceutical Industries Ltd. | Compressed core comprising organic acids for a pharmaceutical composition |
| HUE056194T2 (hu) | 2012-02-21 | 2022-01-28 | Towa Pharmaceutical Europe S L | Dabigatrán-etexilát orális gyógyszerészeti készítményei |
| CN102793699B (zh) | 2012-08-06 | 2014-06-04 | 严轶东 | 一种含有达比加群酯的药用组合物 |
-
2013
- 2013-02-21 HU HUE13704974A patent/HUE056194T2/hu unknown
- 2013-02-21 RS RS20211239A patent/RS62566B1/sr unknown
- 2013-02-21 LT LTEPPCT/EP2013/053426T patent/LT2817000T/lt unknown
- 2013-02-21 CN CN201380010066.2A patent/CN104114158A/zh active Pending
- 2013-02-21 BR BR112014020474-8A patent/BR112014020474B1/pt active IP Right Grant
- 2013-02-21 PL PL13704974T patent/PL2817000T3/pl unknown
- 2013-02-21 AU AU2013224146A patent/AU2013224146B2/en active Active
- 2013-02-21 CN CN201910336600.8A patent/CN110123774A/zh active Pending
- 2013-02-21 KR KR1020147026330A patent/KR102090242B1/ko not_active Expired - Fee Related
- 2013-02-21 EP EP21164447.1A patent/EP3858337A3/en active Pending
- 2013-02-21 SI SI201331940T patent/SI2817000T1/sl unknown
- 2013-02-21 MX MX2014010040A patent/MX368868B/es active IP Right Grant
- 2013-02-21 EP EP13704974.8A patent/EP2817000B1/en active Active
- 2013-02-21 SM SM20210608T patent/SMT202100608T1/it unknown
- 2013-02-21 JO JOP/2013/0057A patent/JO3616B1/ar active
- 2013-02-21 CA CA2864423A patent/CA2864423C/en active Active
- 2013-02-21 IN IN6734DEN2014 patent/IN2014DN06734A/en unknown
- 2013-02-21 ES ES13704974T patent/ES2895918T3/es active Active
- 2013-02-21 JP JP2014558094A patent/JP6215239B2/ja active Active
- 2013-02-21 US US14/379,613 patent/US11013729B2/en active Active
- 2013-02-21 HR HRP20211606TT patent/HRP20211606T1/hr unknown
- 2013-02-21 WO PCT/EP2013/053426 patent/WO2013124340A1/en not_active Ceased
- 2013-02-21 RU RU2014138036A patent/RU2633482C2/ru active
- 2013-02-21 PT PT137049748T patent/PT2817000T/pt unknown
- 2013-02-21 NZ NZ628301A patent/NZ628301A/en unknown
- 2013-02-21 DK DK13704974.8T patent/DK2817000T3/da active
-
2014
- 2014-08-10 IL IL234032A patent/IL234032B/en active IP Right Grant
- 2014-08-11 ZA ZA2014/05855A patent/ZA201405855B/en unknown
-
2021
- 2021-04-27 US US17/241,793 patent/US11752142B2/en active Active
- 2021-10-29 CY CY20211100933T patent/CY1124678T1/el unknown
-
2023
- 2023-07-21 US US18/356,642 patent/US20240139168A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015511241A5 (enExample) | ||
| RU2014138036A (ru) | Пероральные фармацевтические композиции дабигатрана этексилата | |
| JP2016065086A5 (enExample) | ||
| JP2014129360A5 (enExample) | ||
| JP2015535289A5 (enExample) | ||
| JP2016534142A5 (enExample) | ||
| JP2015078230A5 (enExample) | ||
| JP2016512494A5 (enExample) | ||
| JP2015512406A5 (enExample) | ||
| AU2013373885B2 (en) | Oxazolidone compound, preparing method and application thereof | |
| JP2017505822A5 (enExample) | ||
| JP2015510916A5 (enExample) | ||
| JP2013542261A5 (enExample) | ||
| TWI739756B (zh) | 一種含有喹啉衍生物或其鹽的醫藥組成物 | |
| JP2017503014A5 (enExample) | ||
| JP2016027060A5 (enExample) | ||
| WO2015116856A3 (en) | Farnesoid x receptor antagonists | |
| RU2016132762A (ru) | Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением | |
| MX2017004476A (es) | Composicion que comprende al menos un polvo seco obtenido por secado por atomizacion para aumentar la estabilidad de la formulacion. | |
| JP2015514739A5 (enExample) | ||
| TW201202255A (en) | Novel composition for the prevention and/or treatment of thromboembolism | |
| JP6126780B2 (ja) | ロキソプロフェンナトリウム及びトラネキサム酸を含有する固形製剤 | |
| JP2015120758A5 (enExample) | ||
| JP2016512247A5 (enExample) | ||
| EA033291B1 (ru) | Единица дозирования, содержащая рамиприл и бисопролола гемифумарат, способ ее получения и способ лечения гипертензии |